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Abstract: Background: The discovery of the Janus Kinase 2 (JAK2) gene mutation provides a new molecular approach 
for the diagnosis of polycythaemia vera (PV). 
We studied retrospectively patients with a diagnosis of PV at initial presentation to the hospital. They were followed up 
for an initial period of 2 months.  
Objective: The objectives were to access the clinicopathological characteristics, impact of identification of JAK2 mutation 
on diagnosis and treatment strategies.  
Result: Of the 6 patients with complete medical records, 3 were males (50%). The mean haematocrit values were 
59.7%, males had a value of 60.3% while females a values of 59.0%. The total WBC count was 8.8 x 109/L while the 
platelet count was 463.5 x 109/L. None of the patients’ had splenomegaly, all had pruritus. During follow up the mean 
haematocrit values were 52.3%, males had a value of 55.8% while females a values of 48.7%. The total WBC count was 
11.1 x 109/L while the platelet count was 652.1 x 109/L. There was a reduction in the haematocrit value but the white 
blood cell and platelet counts remained high. 
Of the 5 patients who had molecular analysis done, 4(80%) had the JAK2 mutation while in 1 (20%) the mutation was 
not detected. The results of the molecular analysis done in a regional laboratory were received after an average of 21 
days. 
The patients were treated with phlebotomy and hydroxyurea. One patient with increasing thrombocytosis had clopidogrel 
initiated. 3 patients were lost in the follow-up period once there was clinical improvement, at 6 months and 1 year only 1 
patient was left in follow-up. 
Conclusion: The lag time for obtaining results of molecular analysis was long, which made diagnosis and management 
on clinicalbasis.  
This highlights the need for the upgrading of more laboratories to acquire molecular technology for improved patients 
care and diagnostic accuracy. 
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INTRODUCTION 
Chronic myeloproliferative disorders polycythaemia 
vera (PV), essential thrombocythaemia (ET) and 
primary myelofibrosis (PMF) are now called 
myeloproliferative neoplasm’s (MPNs) by the 4th edition 
of the WHO classification of haemopoietic tumors [1]. 
They are disorders due to the clonal proliferation of a 
multipotential haemopoietic stem cell with normal 
maturation and a tendency for extramedullary 
haemopoiesis. Beyond these characteristics, PV, ET 
and PMF share more in common genotypically and 
phenotypically with each other than with the other 
MPNs [2-5]. The tendency for each to acquire the 
phenotypic characteristics of the other makes it worth 
asking whether they are separate disorders, different 
manifestation of the same disease or combination of  
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both. The current molecular evidence supports the last 
possibility [6]. Their initial clinical presentations are also 
highly variable and are subject to change overtime. 
In PV also termed polycythaemia rubra vera, there 
is increased erythrocyte mass, the blood, bone marrow 
spleen and liver are variably involved during 
progression through 2 disease phase, a proliferative or 
polycythaemic phase with increased red cells and a 
post polycythaemic or spent phase with marked 
cytopenias, extramedullary haemopoiesis, hyper- 
splenism and myelofibrosis. A subset may transform to 
acute leukemia.  
Haemorrhage, thrombosis and hyperviscosity 
represent the primary clinical manifestations. 
Thrombotic events include stroke, Deep vein 
thrombosis, Myocardial infarction, Budd - Chiari 
syndrome [7]. Bleeding complications include epistaxis, 
oral mucosal bleeding, gastrointestinal haemorrhages, 
non- specific ecchymoses. Hyperviscosity syndromes 
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from sludging of blood flow and micro thrombi may 
cause hypertension, headache, dizziness, visual 
disturbances vertigo, tinnitus, claudication and 
erythromelagia. Pruritus classically described following 
exposure to warm water results from histamine release 
from activated basophils and mast cells. 
The eligibility criteria for PV were originally created 
by the Polycythaemia Vera Study Group known as the 
PVSG diagnostic criteria. The combination of their 
recommended major and minor criteria (Table 1) 
remained the gold standard for several decades [8]. In 
2001 the WHO classification of PV was published 
(Table 2). This classification included a modernized 
approach to diagnosis by adding several new 
laboratory studies, the classification also aimed at 
applying the Revised European – American lymphoma 
(REAL) classification which was successfully used for 
lymphoid and myeloid neoplasm’s to MPDs [9]. 
The discovery of JAK2 and MPL genetic mutations 
provided new insights into the molecular basis of MPDs 
[10-13]. In 2007 there was a revision in the 4th edition 
of the WHO diagnostic criteria for MPDS to reflect this 
[6, 14]. The objective of identification of JAK 2 mutation 
in patients with clinical manifestation suggestive of PV 
was aimed at diagnostic accuracy, to facilitate targeted 
pharmacotherapeutics and prevent disease 
progression.  
PATIENTS AND METHODS 
Study Population 
The data used were from the medical records of the 
8 patients that a diagnosis of PV was made by 
Consultant Haematologists in the University of Uyo 
Teaching Hospital after reviewing the history, physical 
signs and laboratory investigations in accordance to 
the PVSG diagnostic criteria, from January 2008 – 
December 2015. The follow-up period was two, six 
months and 1year. Two patient’s record were 
incomplete therefore were excluded. 
Permission was sought and obtained in written form 
from the Head of Medical Records Department after 
obtaining Ethical clearance from the Hospital’s Ethical 
committee. 
Table 1: PVSG Diagnostic Criteria for PV 
Major Criteria 
 
 
 
Minor Criteria  
 
 
 
1.  Total red blood cell mass- In males, >36ml/kg; in females >32ml/kg. 
2.  Arterial oxygen saturation > 92%. 
3.  Splenomegaly. 
 
1.  Thrombocytosis with platelet count >400,000/uL. 
2.  Leukocytosis with a white blood cell count >12,000/uL. 
3.  Increased leukocyte alkaline phosphatase > 100U/L. 
4.  Serum vit. B12 concentration > 900 pg/ml or binding capacity > 2200pg/ml.  
*Diagnosis of PV is established with all major criteria or first 2 major criteria plus any 2 minor criteria. 
 
Table 2: WHO Diagnostic Criteria for PV 
A1 Elevated RBC mass > 25% above mean normal predicted value, or Hb> 18.5g/dl in men, 16.5g/dl in women. 
A2 No cause of secondary erythrocytosis, including absence of familial erythrocytosis; no elevated erythropoietin due to 
hypoxia (arterial PO2<92%), high oxygen affinity haemoglobin, truncated erythropoietin receptor, inappropriate 
erythropoietin production by tumor. 
A3 Splenomegaly. 
A4 Clonal genetic abnormality other than Ph chromosome or BCL/ABL fusion gene in marrow cells. 
A5 Endogenous erythroid colony formation in vitro. 
B1 Thrombocytosis >400 x 109/L. 
B2 WBC count >12 x109/L. 
B3 Bone marrow biopsy showing pan myelosis with prominent erythroid and megakaryocytic proliferation. 
B4  Low serum EPO levels 
*PV is diagnosed when A1+A2 +any other A or A1 +A2 + any 2B. RBC indicates red blood cell, Hb, haemoglobin; Ph, Philadelphia; WBC, white blood cell; EPO, 
erythropoietin. 
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Records from the Haematology clinic and 
Haematology Laboratory registers were used to 
authenticate clinic attendance and the laboratory 
results obtained. The JAK2 mutation was analyzed at 
Safety Molecular Laboratory, Owerri, Nigeria, a 
regional reference laboratory using allele specific 
Polymerase chain reaction (PCR).  
RESULTS 
Table 3. shows the demographic and clinical 
characteristics of the patients at diagnosis and during 
the 2 months follow up period. There were 8 patients at 
entry, 2 patients had to be excluded due to poor 
records during follow up. 3 (50%) patients were males 
while 3 (50%) were females. The mean age at 
diagnosis was 57.5 years, 3(50%) were above 60 
years. The mean haematocrit was 59.0% and 52.3% at 
diagnosis and follow up respectively. For males it was 
60.3% and 55.8% at diagnosis and follow up while 
females had 59.0% and 48.7% respectively. 
The total WBC counts 8.8 x 10 9/L and 11.1 x 109/l 
at diagnosis and follow up with 5(83.3%) patients 
having values below 11 x 109/L. The mean platelet 
count was 463.5 x 109/L at diagnosis rising to 652.1 x 
109/L during follow up. 4 (66.7%) patients had platelets 
> 400 x 109/L at diagnosis while 5 (83.3%) had during 
follow up. 
There was no splenomegaly in any of the patients 
while all had pruritus and conjunctival suffusion. There 
was no thrombotic event at diagnosis; one patient had 
a persistent rising thrombocytosis. 3 (50%) patients 
defaulted once there was clinical improvement. At 6 
months and 1 year there was only one patient left in 
Table 3: Demographic and Clinical Characteristics of Patients at Diagnosis and during Follow up 
Variables Patients at Diagnosis Patients In Follow Up 
No of patients No (%) 6 (100) 6 (100) 
Male sex No (%) 3 (50) 3 (50) 
Female sex No (%) 3 (50) 3 (50) 
Mean Age at diagnosis (yrs) 57.5 - 
≤ 60 3 (50) - 
≤ 60 3 (50) - 
Mean Haematocrit (%) 59.7 52.3 
Male 60.3 55.8 
Female 59.0 48.7 
Mean WBC count x 109/ L 8.8 11.1 
≤ 11 5 (83.3) 5 (83.3) 
> 11 1 (16.7) 1 (16.7) 
Mean Platelet x 109/L 463.5 652.1 
≤ 400 2 (33.3) 1 (16.7) 
> 400 4 (66.7) 5 (83.3) 
Splenomegaly Nil Nil 
Thrombotic event Nil 1 (16.7) 
Pruritus 6 (100) Nil 
Conjunctival suffusion 6 (100) Nil 
JAK2 Mutation 4 (66.7)  
Time for obtaining Result in days 21  
Disease Outcome   
 Left treatment facility  3 (50) 
Still in follow up  3 (50) 
Death  Nil 
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follow up. The average time it took for results of JAK2 
analysis to arrive at treatment facility was 21 days.  
DISCUSSION  
The prevalence of PV in the study area was 6.3% 
[15]. In the study in Benin, Nigeria with a larger 
population size, the prevalence was 1.4% [16]. There 
was none recorded in the study done in Ilorin, Nigeria 
[17]. Due to the lack of large population based studies 
in a disease of low frequency [18], the prevalence of 
PV is not well documented. In a unique study in 
Connecticut, USA using health claim records and 
applying it to the entire population of the state, the age-
standardized prevalence of 22 per 100,000 was 
obtained, and is similar to the Italian and Swedish 
studies [19]. The lower frequencies in the studies in 
developing countries needs to be further analyzed in a 
larger multi-centered study program. In this study there 
are 3 males (50%) and 3 females (50%) at 
presentation, the mean haematocrit value was 59.7%. 
The males had a value of 60.3% while in females it was 
59%. There was no statistical significant difference. 
This absence of statistical difference may be age 
related as most of the females were above 60 years. 
In the follow up patients there was a significant 
reduction (P<0.01) in the haematocrit value to 52.3%. 
The males and females had a value of 55.8% and 
48.7% respectively. This was in response to 
phlebotomy. 
The tWBC at presentation was 8.8 x 10 9/L and 
there was a progressive increase to 11.1 x10 9/L in the 
follow up period despite initiation of hydroxurea a 
cytoreductive therapy. 
The platelet count at presentation was 463.5 x10 9/L 
with a statistical significant increase to 652.1 x10 9/L in 
the follow up (P< 0.001) despite the cytoreductive 
therapy. The persistence and rising thrombocytosis 
necessitated the addition of clopidogrel an anti-platelet 
drugs in one of the patient. Acetylsalicylic acid was 
used for the other patients in the follow-up period. 
The average time for obtaining the results of the 
JAK2 analysis was 21 days; this is outside the time it 
takes to educate and counsel the patient’s family to 
bear the cost of the test. Applied in this manner the 
identification of JAK2 mutation may only improve 
diagnostic accuracy. The initiation of targeted 
pharmacotherapeutics with anti-JAK2 properties would 
have been of benefit to the patient’s outcome as rising 
WBC counts and platelet counts are risk factors for 
thrombotic events [20]. 
CONCLUSION  
The impact of the identification of JAK2 mutation in 
patients with PV- like symptoms offers diagnostic 
accuracy but needs to be readily available and 
affordable to improve the quality of management of 
cancer patients in developing countries.  
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